| Date | Title | Description |
| 26.08.2024 | Cyxone AB announces last day of trading in BTA | Cyxone AB announces last day of trading in BTA
Mon, Aug 26, 2024 14:19 CET Report this content
Cyxone AB’s ("Cyxone" or the "Company") rights issue, with a subscription period ending on 15 August 2024, has now been regis... |
| 16.08.2024 | Cyxone AB publishes outcome of rights issue | Cyxone AB publishes outcome of rights issue
Fri, Aug 16, 2024 08:59 CET Report this content
The subscription period in Cyxone AB’s ("Cyxone" or the "Company") rights issue ended on 15 August 2024 (the "Rights Issue&... |
| 03.08.2024 | Cyxone's Rights Issue: A Crucial Step Towards Innovation in Autoimmune Treatments | Cyxone AB, a Swedish biopharmaceutical company, is making waves in the healthcare sector. Today marks the beginning of a pivotal moment for the company: the subscription period for its rights issue. This initiative aims to raise up to SEK 2... |
| 01.08.2024 | The subscription period in Cyxone’s rights issue starts today | The subscription period in Cyxone’s rights issue starts today
Thu, Aug 01, 2024 08:45 CET Report this content
Today, 1 August 2024, the subscription period in Cyxone AB’s ("Cyxone" or "the Company") issue of shares (the ... |
| 31.07.2024 | Cyxone AB publishes investment memorandum | Cyxone AB publishes investment memorandum
Wed, Jul 31, 2024 08:45 CET Report this content
On 23 July 2024, the board of Cyxone AB (publ) ("Cyxone" or the "Company"), resolved to carry out a preferential rights issue of s... |
| 23.07.2024 | The board decides on a rights issue of a maximum of approximately SEK 23 million to finance continued development of rabeximod and T20K | The board decides on a rights issue of a maximum of approximately SEK 23 million to finance continued development of rabeximod and T20K
Tue, Jul 23, 2024 08:30 CET Report this content
The board of Cyxone AB (publ), corporate no. 559020-5471... |
| 15.07.2024 | Cyxone provides an update on its research and development program | Cyxone provides an update on its research and development program
Mon, Jul 15, 2024 08:42 CET Report this content
Cyxone (publ) is a biotech company with two promising clinical stage drug candidates, rabeximod and T20K, for autoimmune disea... |
| 22.04.2024 | Kjell Stenberg new CEO in Cyxone AB | Kjell Stenberg new CEO in Cyxone AB
Mon, Apr 22, 2024 10:02 CET Report this content
Cyxone AB (publ), a biotech company in autoimmune diseases, has decided to appoint Kjell Stenberg as new CEO with immediate effect. Kjell replaces Carl-Magn... |
| 25.03.2024 | Cyxone enters important research collaboration | Cyxone enters important research collaboration
Mon, Mar 25, 2024 13:44 CET Report this content
Cyxone (publ), a biotech company in autoimmune diseases, enters into a strategically important research collaboration with an acknowledged resear... |
| 27.10.2023 | Interim Report 1 January to 30 September 2023 | Interim Report 1 January to 30 September 2023
Fri, Oct 27, 2023 08:29 CET Report this content
Financial Summary for the group
KSEK 2023-07-01 2022-07-01 2023-01-01 2022-01-01
2023-09-30 2022-09-30 2023-09-30 2022-09-30
Net turnover 0 0 0 0
... |
| 30.08.2023 | Interim Report 1 January to 30 June 2023 | Interim Report 1 January to 30 June 2023
Wed, Aug 30, 2023 08:32 CET Report this content
Financial Summary for the group
KSEK 2023-04-01 2022-04-01 2023-01-01 2022-01-01
2023-06-30 2022-06-30 2023-06-30 2022-06-30
Net turnover 0 0 0 0
Profi... |
| 29.08.2023 | Cyxone revises strategy for commercial alignment targeting valuable market opportunities | Cyxone revises strategy for commercial alignment targeting valuable market opportunities
Tue, Aug 29, 2023 19:03 CET Report this content
Cyxone (publ), a biotech company in autoimmune diseases, with its lead asset rabeximod under developmen... |
| 15.06.2023 | Cyxone appoints Urban Ottosson as new CFO | Cyxone appoints Urban Ottosson as new CFO
Thu, Jun 15, 2023 08:30 CET Report this content
Cyxone (publ), a biotech company in autoimmune diseases, has recruited Urban Ottosson as new Chief Financial Officer (CFO) as of June 15th 2023, repla... |
| 12.05.2023 | Interim Report 1 January to 31 March 2023 | Interim Report 1 January to 31 March 2023
Fri, May 12, 2023 08:22 CET Report this content
Financial Summary for the group
KSEK 2023-01-01 2022-01-01
2023-03-31 2022-03-31
Net turnover 0 0
Profit/loss before tax -5 976 -16 679
Total assets 4... |
| 09.05.2023 | Cyxone receives patent approval from the US for the salt forms of the compound rabeximod | Cyxone receives patent approval from the US for the salt forms of the compound rabeximod
Tue, May 09, 2023 13:45 CET Report this content
Cyxone (publ), a biotech company in autoimmune diseases, is pleased to announce that the company has ob... |
| 26.04.2023 | Notice of annual general meeting in Cyxone AB | Notice of annual general meeting in Cyxone AB
Wed, Apr 26, 2023 11:38 CET Report this content
The English text is an unofficial translation. In case of any discrepancies between the Swedish language version of this document and the English ... |
| 31.03.2023 | Notice of extraordinary general meeting in Cyxone AB | Notice of extraordinary general meeting in Cyxone AB
Fri, Mar 31, 2023 15:35 CET Report this content
The English text is an unofficial translation. In case of any discrepancies between the Swedish language version of this document and the E... |
| 17.02.2023 | Year-end Report 1 January to 31 December 2022 | Year-end Report 1 January to 31 December 2022
Fri, Feb 17, 2023 08:30 CET Report this content
Financial Summary for the group
KSEK 2022-10-01 2021-10-01 2022-01-01 2021-01-01
2022-12-31 2021-12-31 2022-12-31 2021-12-31
Net turnover 0 0 0 0
... |
| 08.11.2022 | Nomination committee appointed for Cyxone Annual General Meeting 2023 | Nomination committee appointed for Cyxone Annual General Meeting 2023
Tue, Nov 08, 2022 13:35 CET Report this content
Cyxone AB (publ) hereby announces that the members of the nomination committee have been appointed ahead of the 2023 AGM. ... |
| 27.10.2022 | Interim Report 1 January to 30 September 2022 | Interim Report 1 January to 30 September 2022
Thu, Oct 27, 2022 08:30 CET Report this content
Financial Summary for the group
KSEK 2022-07-01 2021-07-01 2022-01-01 2021-01-01
2022-09-30 2021-09-30 2022-09-30 2021-09-30
Net turnover 0 0 0 0
... |
| 02.09.2022 | Cyxone appoints Erika Samuelsson as Chief Development Officer | Cyxone appoints Erika Samuelsson as Chief Development Officer
Fri, Sep 02, 2022 11:01 CET Report this content
Cyxone (publ), a biotech company in autoimmune diseases, announces today that Erika Samuelsson has been appointed new Chief Develo... |
| 31.08.2022 | Ola Skanung new CFO at Cyxone, replacing Henrik Hang | Ola Skanung new CFO at Cyxone, replacing Henrik Hang
Wed, Aug 31, 2022 15:00 CET Report this content
Cyxone (publ), a biotech company in autoimmune diseases, announces today that CFO Henrik Hang leaves the company at his own request. Ola Sk... |
| 24.08.2022 | Interim Report 1 January to 30 June 2022 | Interim Report 1 January to 30 June 2022
Wed, Aug 24, 2022 08:30 CET Report this content
Financial Summary for the group
KSEK 2022-04-01 2021-04-01 2022-01-01 2021-01-01
2022-06-30 2021-06-30 2022-06-30 2021-06-30
Net turnover 0 0 0 0
Profi... |
| 17.05.2022 | First Berlin Equity Research publishes independent analysis of Cyxone | First Berlin Equity Research publishes independent analysis of Cyxone
Tue, May 17, 2022 15:36 CET Report this content
Cyxone (publ), a biotech company in autoimmune diseases, announces today that the internationally renowned research compan... |
| 16.05.2022 | Bulletin from the annual general meeting in Cyxone AB on 16 May 2022 | Bulletin from the annual general meeting in Cyxone AB on 16 May 2022
Mon, May 16, 2022 11:00 CET Report this content
Today, on 16 May 2022, the annual general meeting was held in Cyxone AB. A summary of the adopted resolutions follows below... |
| 12.05.2022 | Interim Report 1 January to 31 March 2022 | Interim Report 1 January to 31 March 2022
Thu, May 12, 2022 08:30 CET Report this content
Financial Summary for the group
KSEK 2022-01-01 2021-01-01
2022-03-31 2021-03-31
Net turnover 0 0
Profit/loss before tax -16 679 -8 612
Total assets 8... |
| 12.05.2022 | Adjusted proposal regarding election and remuneration of board members prior to the Annual General Meeting of Cyxone AB | Adjusted proposal regarding election and remuneration of board members prior to the Annual General Meeting of Cyxone AB
Thu, May 12, 2022 16:55 CET Report this content
The two largest individual shareholders in Cyxone AB, Ivar Nordqvist and... |
| 03.05.2022 | Cyxone AB announces promising T20K/KORa combination therapy efficacy in preclinical therapeutic model of MS | Cyxone AB announces promising T20K/KORa combination therapy efficacy in preclinical therapeutic model of MS
Tue, May 03, 2022 10:07 CET Report this content
Cyxone AB (CYXO), a clinical-stage company developing transformative therapies in th... |
| 28.04.2022 | Cyxone announces forward looking drug development strategy with focus on Rabeximod in Rheumatoid Arthritis trial | Cyxone announces forward looking drug development strategy with focus on Rabeximod in Rheumatoid Arthritis trial
Thu, Apr 28, 2022 11:01 CET Report this content
Cyxone AB (CYXO), a clinical-stage company developing transformative therapies ... |
| 28.04.2022 | Cyxone AB (CYXO) Introduced at the online HC Andersen Capital event on 29 April | Cyxone AB (CYXO) Introduced at the online HC Andersen Capital event on 29 April
Thu, Apr 28, 2022 13:23 CET Report this content
Cyxone’s CEO Tara Heitner will present an introduction to the company on Friday 29 April 2022 at 11.00-11.30 at ... |
| 13.04.2022 | Annual Report from Cyxone AB for the period 1 January 2021 to 31 December 2021 | Annual Report from Cyxone AB for the period 1 January 2021 to 31 December 2021
Wed, Apr 13, 2022 16:48 CET Report this content
Cyxone AB’s Annual Report for the financial year 2021 is now available at the company’s website (www.cyxone.com).... |
| 12.04.2022 | Notice of annual general meeting in Cyxone AB | Notice of annual general meeting in Cyxone AB
Tue, Apr 12, 2022 13:30 CET Report this content
The English text is an unofficial translation. In case of any discrepancies between the Swedish language version of this document and the English ... |
| 01.04.2022 | Safety confirmation and observed trends in Covid-19 study build further confidence in Cyxone’s rheumatoid arthritis program | Safety confirmation and observed trends in Covid-19 study build further confidence in Cyxone’s rheumatoid arthritis program
Fri, Apr 01, 2022 08:26 CET Report this content
Cyxone AB (publ), the Swedish biotech company that develops disease ... |
| 23.02.2022 | Cyxone’s CMO departs the company | Cyxone’s CMO departs the company
Wed, Feb 23, 2022 08:30 CET Report this content
Cyxone (publ) announces today that Chief Medical Officer (CMO) Cornel Pater leaves the company with immediate effect due to personal reasons. The planned Phase... |
| 22.02.2022 | Year-end Report 1 January to 31 December 2021 | Year-end Report 1 January to 31 December 2021
Tue, Feb 22, 2022 08:30 CET Report this content
Financial Summary for the group
KSEK 2021-10-01 2020-10-01 2021-01-01 2020-01-01
2021-12-31 2020-12-31 2021-12-31 2020-12-31
Net turnover 0 0 0 0
... |
| 25.01.2022 | Cyxone announces outcome of the rights issue | Cyxone announces outcome of the rights issue Tue, Jan 25, 2022 19:31 CET
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGA... |
| 18.01.2022 | Cyxone takes next step in Multiple Sclerosis program engaging Contract Development & Manufacturing Organization for production of T20K | Cyxone takes next step in Multiple Sclerosis program engaging Contract Development & Manufacturing Organization for production of T20K Tue, Jan 18, 2022 08:46 CET
Cyxone (publ) announces today that the company has engaged a renowned Eur... |
| 10.01.2022 | Cyxone step up activities and extend collaboration with global CRO around RA trial | Cyxone step up activities and extend collaboration with global CRO around RA trial Mon, Jan 10, 2022 08:35 CET
Cyxone (publ) announces today that the company has signed a Letter of Agreement (LOA) with the internationally renowned clinical ... |
| 23.12.2021 | Cyxone publishes prospectus due to the upcoming rights issue | Cyxone publishes prospectus due to the upcoming rights issue Thu, Dec 23, 2021 10:21 CET
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NE... |
| 21.12.2021 | Cyxone executes a rights issue of SEK 66.9 million secured to 91 % ahead of the Phase 2b study in RA | Cyxone executes a rights issue of SEK 66.9 million secured to 91 % ahead of the Phase 2b study in RA Tue, Dec 21, 2021 08:59 CET
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA,... |
| 17.12.2021 | Cyxone reports publication of four patent applications pertaining to its drug candidate Rabeximod | Cyxone reports publication of four patent applications pertaining to its drug candidate Rabeximod Fri, Dec 17, 2021 13:36 CET
Cyxone (publ) today announces that four patent applications pertaining to its drug candidate Rabeximod have been p... |
| 14.12.2021 | Cyxone initiates early operations with a global contract research organization to conduct Phase 2b trial in rheumatoid arthritis | Cyxone initiates early operations with a global contract research organization to conduct Phase 2b trial in rheumatoid arthritis Tue, Dec 14, 2021 13:02 CET
Cyxone (publ) announces today that the company has initiated an early operations ag... |
| 09.12.2021 | Cyxone files patent application with potential to extend market exclusivity of the drug candidate Rabeximod | Cyxone files patent application with potential to extend market exclusivity of the drug candidate Rabeximod Thu, Dec 09, 2021 16:17 CET
Cyxone (publ) today announces that the company has filed a new patent application for Rabeximod with pat... |
| 06.12.2021 | Cyxone presents top-line results from a phase 2 study of Rabeximod in Covid-19 patients | Cyxone presents top-line results from a phase 2 study of Rabeximod in Covid-19 patients Mon, Dec 06, 2021 08:45 CET
Cyxone (publ) today announces top-line results from a phase 2 study of Rabeximod in Covid-19 patients with moderate disease.... |
| 30.11.2021 | Cyxone announces change of Certified Adviser to FNCA | Cyxone announces change of Certified Adviser to FNCA Tue, Nov 30, 2021 14:15 CET
Cyxone AB (publ), Reg. No. 559020-5471 (the ”Company”), hereby announces that the Company has entered into an agreement with FNCA Sweden AB (”FNCA”) regarding ... |
| 29.10.2021 | Interim Report 1 January to 30 September 2021 | Interim Report 1 January to 30 September 2021 Fri, Oct 29, 2021 08:31 CET
Financial Summary for the group
KSEK 2021-07-01 2020-07-01 2021-01-01 2020-01-01
2021-09-30 2020-09-30 2021-09-30 2020-09-30
Profit/loss before tax -10 974 -12 620 -3... |
| 26.10.2021 | Cyxone announces promising preclinical results supporting T20K combination therapy for multiple sclerosis | Cyxone announces promising preclinical results supporting T20K combination therapy for multiple sclerosis Tue, Oct 26, 2021 08:56 CET
Cyxone (publ) announces today that the company, together with its academic partner Medical University of V... |
| 24.09.2021 | Cyxone will leverage IND and use FDA pre-review for Covid-19 phase 2 trial | Cyxone will leverage IND and use FDA pre-review for Covid-19 phase 2 trial Fri, Sep 24, 2021 11:19 CET
Cyxone AB (publ) announces today that the company is expecting to communicate top-line results from a recently concluded Phase 2 trial of... |
| 01.09.2021 | Cyxone appoints Cornel Pater as new Chief Medical Officer | Cyxone appoints Cornel Pater as new Chief Medical Officer Wed, Sep 01, 2021 11:56 CET
Cyxone today announced that Cornel Pater has been appointed as the company’s new Chief Medical Officer (CMO). Most recently, he held the position as Globa... |
| 27.08.2021 | Interim Report 1 January to 30 June 2021 | Interim Report 1 January to 30 June 2021 Fri, Aug 27, 2021 08:30 CET
Financial Summary for the group
KSEK Q2 Q2 Q1-Q2 Q1-Q2
2021 2020 2021 2020
Profit/loss before tax -11 458 -14 197 -20 069 -24 394
Total assets 69 240 58 357 69 240 58 357
... |
| 26.08.2021 | Cyxone recruits key members to the clinical development team | Cyxone recruits key members to the clinical development team Thu, Aug 26, 2021 13:34 CET
Cyxone today announced that the company has recruited Anna Polak and Levente Dajka as members of the Cyxone development team. Both will bring vast know... |
| 14.07.2021 | Cyxone announces Rabeximod in Covid-19 Phase 2 trial closed, data to be reported in Q3 | Cyxone announces Rabeximod in Covid-19 Phase 2 trial closed, data to be reported in Q3 Wed, Jul 14, 2021 08:41 CET
Cyxone today announced that the Rabeximod in Covid-19 trial that has been conducted in Eastern Europe during Q1-Q2 2021 will ... |
| 09.06.2021 | Cyxone appoints Henrik Hang as CFO | Cyxone appoints Henrik Hang as CFO Wed, Jun 09, 2021 15:51 CET
Cyxone AB (publ) (“Cyxone or the Company”) has appointed Henrik Hang as new CFO as of August 1st, 2021. Henrik has a degree in business administration and substantial experience... |
| 03.06.2021 | Bulletin from the annual general meeting in Cyxone AB on 3 June 2021 | Bulletin from the annual general meeting in Cyxone AB on 3 June 2021 Thu, Jun 03, 2021 13:55 CET
The English text is an unofficial translation. In case of any discrepancies between the Swedish language version of this document and the Engli... |
| 01.06.2021 | Cyxone AB (publ) receives approximately SEK 18.2 million through exercised warrants of series TO4 | Cyxone AB (publ) receives approximately SEK 18.2 million through exercised warrants of series TO4 Tue, Jun 01, 2021 16:50 CET
Today, Cyxone AB (publ) ("Cyxone" or the "Company") announces the outcome of the exercise of w... |
| 21.05.2021 | The last day of trading with warrants of series TO4 in Cyxone AB is today, May 21, 2021 | The last day of trading with warrants of series TO4 in Cyxone AB is today, May 21, 2021 Fri, May 21, 2021 08:40 CET
Today, May 21, 2021, is the last day of trading with warrants of series TO4 in Cyxone AB (publ) (“Cyxone” or “the Company”).... |
